Skip to main content

Yesterday, Jan. 6, 2016, 63 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $29.28 to $2,872,125.00.

Highlighted Stocks Traded by Insiders:

Foundation Medicine (FMI) - FREE Research Report

Miller Vincent A., who is Chief Medical Officer at Foundation Medicine, sold 328 shares at $19.88 on Jan. 6, 2016. Following this transaction, the Chief Medical Officer owned 78,838 shares meaning that the stake was reduced by 0.41% with the 328-share transaction.

Kafka Steven J., who is President & COO at Foundation Medicine, sold 112 shares at $19.88 on Jan. 6, 2016. Following this transaction, the President & COO owned 41,350 shares meaning that the stake was reduced by 0.27% with the 112-share transaction.

The shares most recently traded at $16.76, down $3.12, or 18.62% since the insider transaction. Historical insider transactions for Foundation Medicine go as follows:

  • 4-Week # shares bought: 9,100
  • 4-Week # shares sold: 2,559
  • 12-Week # shares bought: 9,100
  • 12-Week # shares sold: 2,559
  • 24-Week # shares bought: 9,100
  • 24-Week # shares sold: 2,979

The average volume for Foundation Medicine has been 319,300 shares per day over the past 30 days. Foundation Medicine has a market cap of $681.8 million and is part of the health care sector and health services industry. Shares are down 12.16% year-to-date as of the close of trading on Wednesday.

Foundation Medicine, Inc. provides various molecular information products in the United States. Currently, there is 1 analyst who rates Foundation Medicine a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FMI - FREE

TheStreet Quant Ratings

TheStreet Recommends

rates Foundation Medicine as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. Get the full

Foundation Medicine Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

KLA-Tencor (KLAC) - FREE Research Report

Bell Bobby R, who is Executive Vice President at KLA-Tencor, sold 6,343 shares at $68.05 on Jan. 6, 2016. Following this transaction, the Executive Vice President owned 6,691 shares meaning that the stake was reduced by 48.67% with the 6,343-share transaction.

The shares most recently traded at $66.00, down $2.05, or 3.11% since the insider transaction. Historical insider transactions for KLA-Tencor go as follows:

  • 4-Week # shares sold: 1,600
  • 12-Week # shares bought: 67
  • 12-Week # shares sold: 24,716
  • 24-Week # shares bought: 67
  • 24-Week # shares sold: 60,735

The average volume for KLA-Tencor has been 2.3 million shares per day over the past 30 days. KLA-Tencor has a market cap of $10.7 billion and is part of the technology sector and electronics industry. Shares are down 3.99% year-to-date as of the close of trading on Wednesday.

KLA-Tencor Corporation designs, manufactures, and markets process control and yield management solutions worldwide. The stock currently has a dividend yield of 3.03%. The company has a P/E ratio of 27.8. Currently, there are 4 analysts who rate KLA-Tencor a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KLAC - FREE

TheStreet Quant Ratings

rates KLA-Tencor as a

hold

. The company's strengths can be seen in multiple areas, such as its increase in net income, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full

KLA-Tencor Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific (BSX) - FREE Research Report

Ballinger Kevin J., who is SVP & Pres, Interven Cardio at Boston Scientific, sold 16,114 shares at $18.00 on Jan. 6, 2016. Following this transaction, the SVP & Pres, Interven Cardio owned 49,382 shares meaning that the stake was reduced by 24.6% with the 16,114-share transaction.

Mirviss Jeffrey B., who is SVP&Pres, Periph Intervent at Boston Scientific, sold 9,953 shares at $18.00 on Jan. 6, 2016. Following this transaction, the SVP&Pres, Periph Intervent owned 82,535 shares meaning that the stake was reduced by 10.76% with the 9,953-share transaction.

The shares most recently traded at $17.82, down $0.18, or 1.01% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares bought: 11,700
  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 11,700
  • 12-Week # shares sold: 195,279
  • 24-Week # shares bought: 11,700
  • 24-Week # shares sold: 202,192

The average volume for Boston Scientific has been 9.0 million shares per day over the past 30 days. Boston Scientific has a market cap of $24.5 billion and is part of the health care sector and health services industry. Shares are down 2.39% year-to-date as of the close of trading on Wednesday.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Currently, there are 14 analysts who rate Boston Scientific a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings

rates Boston Scientific as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full

Boston Scientific Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.